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Prognostic signiﬁcance of immunohistochemically detected breast
cancer node metastases in 218 patients
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Axillary lymph node metastases detected by immunohistochemistry in standard node-negative patients with breast carcinomas
(13 out of 129 inﬁltrating ductal carcinomas and 37 out of 89 inﬁltrating lobular carcinomas) do not have any prognostic
signiﬁcance in patients followed up for a long time (respectively 24 and 18 years). Moreover, their pejorative signiﬁcance in the
literature is debatable since the groups and events taken into account are heterogeneous.
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Previous studies on the prognostic signiﬁcance of axillary node
metastases detected by immunohistochemical stainings (IHM) in
invasive breast cancer have focused on a variable number of cases
with different histological sampling techniques and statistical meth-
ods. The prognostic signiﬁcance of such metastases is still debated
and their clinical management is controversial. In our two
previously published groups (Trojani et al, 1987a,b) of patients
(grouped together in the present study under the name ‘study
1’–1987), nodal metastases detected by immunohistochemistry
were associated with shorter metastasis-free probability (MFP)
and overall survival probability (OSP) in the inﬁltrating ductal
carcinoma node-negative group of patients (IDC, median follow-
up: 10 years, Trojani et al, 1987a) but not in the inﬁltrating lobular
carcinoma node-negative group of patients (ILC, median follow-
up: 6.5 years, Trojani et al, 1987b). In the same two groups of
patients with a longer follow-up (median follow-up: 15.6 years in
the IDC group and 9.3 years in the ILC group, ‘study 2’–1992,
de Mascarel et al, 1992), these IHM were still associated in the
IDC group with a shorter MFP, but survival was not different
between patients with or without metastases. In the ILC group
there was still no difference in MFP and OSP between patients with
or without metastases.
The aim of the present study (‘study 3’–2001) was to use longer
follow-up to assess the prognostic signiﬁcance of metastases
detected by immunohistochemical stainings in these two IDC
and ILC groups of patients with node-negative breast carcinomas.
MATERIALS AND METHODS
Patients
From 1965 to 1984, 2768 patients with distant metastasis-free
breast cancer underwent surgery at Institut Bergonie ￿. They were
prospectively included in our clinical, histological and biological
database and followed up at our institution. In 1987 129 node-
negative patients were selected with inﬁltrating ductal carcinomas
(IDC) operated on between 1965 and 1977 (Trojani et al, 1987a)
and 89 node-negative patients with inﬁltrating lobular carcinoma
(ILC) operated on between 1965 and 1984 (Trojani et al, 1987b).
All slides of tumours and lymph nodes were reviewed by a senior
pathologist (IM) and the distribution of clinical and pathological
criteria are summarised in Table 1. All the patients were treated
by Patey type mastectomy and axillary node dissection (only ﬁve
patients without IHM in the IDC group and one in the ILC group
received a brief course of chemotherapy). In the IDC and ILC
groups, respectively 24 and 30 patients received radiotherapy.
Among the 129 patients with IDC (median follow-up: 24 years),
26 had distant metastases (20%) and 67 died (52%). Among the
89 patients with ILC (median follow-up: 18 years), 16 had distant
metastases (18%) and 37 died (41.5%).
Macroscopic lymph node processing: macroscopic serial
sectioning
The mean number of lymph nodes analysed in each case was 14
(range 2–29). Since 1965 all axillary lymph nodes have been exam-
ined at our institute by macroscopic serial sectioning. After ﬁxation
in Bouin-Holland, each node is macroscopically cut entirely into
1–1.5 mm thick slices perpendicular to the long axis (one to nine
slices, mean: four). All slices of one node are placed together in as
many numbered cassettes as necessary and parafﬁn-embedded. The
number of cassettes (parafﬁn blocks) required to analyse each
entire node ranged from one (90% of the cases) to three. Each
block is examined on one haematoxylin-eosin-safran (HES) stained
slide. Thus, in 90% of the cases all the slices of one node were situ-
ated on one HES slide (Figure 1A).
Immunohistochemical stainings
Immunostaining was performed on the original diagnostic HES-
stained slides of the axillary nodes. These were the same sections
in which metastases were considered to be negative by routine
HES examination. They were successively destained and restained
by a three-stage immunoperoxidase procedure with a cocktail of
ﬁve monoclonal antibodies against epithelial cell antigens (Trojani
et al, 1987a,b). IHM were found in 37 ILC (41%) and in 13 IDC
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node dissection in the IDC group and in one (26%), two (6%),
three (6%) or four (3%) lymph nodes per dissection in the ILC
group. In all the cases IHM were unequivocal but morphologically
different according to the histological type. In IDC, they corre-
sponded to small tumour cell clusters in the subcapsular sinuses
ranging from 0.01 to 0.2 mm in size, whereas in ILC, they corre-
sponded to a variable number of isolated tumour cells with an
irregular distribution, sometimes throughout the entire node
sections. These isolated cells were neither counted nor measured.
Statistical analysis
Metastasis-free probability (MFP) and overall survival probability
(OSP) were calculated from the date of surgery to the occurrence
of distant metastasis or to death. Life tables were calculated accord-
ing to the Kaplan–Meier method. In the IDC and ILC groups, we
compared MFP and OSP between the patients with and without
IHM using the log-rank test (software SPSS 9.01, SPSS Inc
1989–1999).
RESULTS
The distribution of distant metastases and deaths in relation to the
presence or the absence of node metastases detected by immuno-
histochemistry in the two groups is summarised in Table 2. In
neither group were there any signiﬁcant differences in MFP
(Figures 2 and 3) or OSP between patients with and without IHM.
DISCUSSION
Analysis of our study
The relatively small number of patients and events requires caution
in the interpretation of these results. Nevertheless, our ILC group is
the largest published to date. In 1987, events taken into account to
calculate survival probabilities were different from now and
included distant metastases and loco-regional recurrences for
recurrence-free probability and only deaths from cancer for survi-
val. However, the results are the same when taking into account
the same events as those in 1987. Furthermore, as regards patients
who received radiotherapy vs those who did not, it has been
proved that radiotherapy decreases locoregional recurrences but
has no inﬂuence on MFP or OSP in node–negative patients (Rutq-
vist et al, 1993). Lastly, although the serial macroscopic sectioning
method is now recommended (Fitzgibbons et al, 2000), our study
is the only series to date with serial macroscopic sectioning and
with such a long follow-up. In our series, serial macroscopic
sectioning and IH stainings on the original sections may explain
the small size of IHM, all of which were occult metastases. They
could be termed micrometastases in the IDC group because they
were much smaller than 2 mm in size. On the other hand, the
use of such a term is debatable in the ILC group since they corre-
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Table 1 Distribution of clinical and pathological criteria in the inﬁltrating
ductal carcinoma (IDC) and in the inﬁltrating lobular carcinoma (ILC) pa-
tient groups (218 patients)
Inﬁltrating
ductal
carcinoma
(n=129)
Inﬁltrating
lobular
carcinoma
(n=89)
No. (%) No. (%)
Age
450 years 34 (27) 27 (30)
450 years 94 (73) 62 (70)
Clinical tumour size
non-palpable tumour 2 (2) 4 (55)
1–20 mm 65 (50) 27 (30)
21–50 mm 43 (33) 47 (53)
450 mm 15 (12) 10 (11)
TX 4 (3) 1 (1)
Grade
I 24 (19) ND*
II 59 (46) ND
III 42 (32) ND
Not speciﬁed 4 (3) 89
Obvious peritumoral emboli
Absent 102 (79) 84 (94)
Present 24 (19) 2 (2)
Not speciﬁed 3 (2) 3 (4)
ND=not done.
1 to 1.5 mm
2 mm
2 mm
2 mm
2 mm
One block with five slices from one node One block with four slices from four nodes
A
B
Figure 1 Macroscopic lymph node processing. (A) Macroscopic serial sectioning. (B) Standard sectioning.
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irregularly distributed, sometimes throughout the entire lymph
node sections. Finally, our results underline the importance of
length of follow-up in assessing the prognostic signiﬁcance of
metastases detected by immunohistochemistry, since the difference
in MFP between patients with and without IHM was no longer
statistically signiﬁcant in the IDC group. Whatever the cases, differ-
ences in MFP at 10 years may still be clinically relevant even if no
differences are subsequently apparent, although they do not justify
using such a single criterion to initiate chemotherapy. On the
contrary, in ILC the difference between true node-negative and
IHM was not signiﬁcant at any time point. Thus, these differences
in frequency, histological pattern and variability of prognostic
signiﬁcance according to histological type suggest that a difference
in nature might exist between IHM in IDC and IHM in ILC.
Analysis of other studies
Some authors have attempted to summarise studies on axillary
micrometastases (Dowlatshahi et al, 1997), but the complexity
and heterogeneity of the methodologies used have made the task
difﬁcult. We analysed the results of the 11 published series regard-
ing the prognostic signiﬁcance of metastases detected by
immunohistochemistry (Byrne et al, 1987, 1992; Trojani et al,
1987a,b; Sedmak et al, 1989; Chen et al, 1991; Galea et al, 1991;
Noe ¨l et al, 1991; de Mascarel et al, 1992; Elson et al, 1993; Hains-
worth et al, 1993; Nasser et al, 1993; McGuckin et al, 1996; Cote et
al, 1999) by comparing size and type of populations, histological
tumour types, lymph node processing, immunohistochemical stain-
ings and statistical analyses (Table 3). Only one series was
prospective (Cote et al, 1999). Contrary to our study, a standard
macroscopic technique was used in all the other studies, i.e. each
lymph node was examined on one 2–3 mm thick slice transected
in the major axis (Figure 1B). The mean number of lymph nodes
per axillary node dissection was variable, and immunohistochem-
ical stainings were performed either on original destained slides
(Byrne et al, 1987; Trojani et al, 1987a,b; Noe ¨l et al, 1991; Byrne
et al, 1992) or on slides from recuts of each block (Sedmak et
al, 1989; Chen et al, 1991; Galea et al, 1991; Elson et al, 1993;
Hainsworth et al, 1993; Nasser et al, 1993; McGuckin et al, 1996;
Cote et al, 1999). The latter approach cannot distinguish between
metastases that would be identiﬁable at deeper levels without
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Figure 2 Metastasis-free survival according to presence or absence of node metastases detected by immunohistochemistry (IHM) in IDC group.
Table 2 Distribution of events (distant metastases or deaths) in our studies according to the presence or the absence of metastases detected by immu-
nohistochemistry (IHM) in the inﬁltrating ductal carcinoma (IDC) and inﬁltrating lobular carcinoma (ILC) groups
Study 1, 1987
a Study 2, 1992 Study 3, 2001
IHM IHM IHM
Pos Neg P-value
Median
(years) Pos Neg P-value
Median
(years) Pos Neg P-value
Median
(years)
Distant metastases
IDC 4 9 0.002 (S) 5 15 0.01 (S) 5 21 0.07
ILC 3 5 0.9 4 5 0.07 7 9 0.6
IDC: 10
ILC: 6.5
IDC: 15.6
ILC: 9.3
IDC: 24
ILC: 18
Deaths
IDC 3 7 0.02 (S) 5 42 0.8 6 61 0.7
ILC 2 2 0.5 7 10 0.08 19 18 0.07
M=median follow-up (years); S=signiﬁcant difference.
aIn 1987 study: 122 IDC and 91 ILC; in 1992 and 2001 studies 129 IDC and 89 ILC.
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Table 3 Frequency and prognostic signiﬁcance of metastases detected by immunohistochemical staining (IHM) in the literature
Histological type IHM Recurrences Survival
Author (date) IHS method No. Type No. (%)
Follow-up: median
years Events P-value Events P-value
Trojani et al (1987) Original slides 150 122 IDC 13 (11) 10 DFP 0.002 U SS 0.02
21 ILC 8 (38) DFP 0.001 M SS 0.01
Trojani et al (1987) Original slides 91 91 ILC 8 (38) 6.5 DFP NS U SS
a NS
Byrne et al (1987) Original slides 40 NSp 4 (10) 5 DFP NS U OS NS
Sedmak et al (1989) Recuts 45 3 DCIS 9 (20) 10 NSp U NSp 0.05
1 medullary
41 IDC
Galea et al (1991) Recuts 98 NSp 9 (9) 14 NSp NS U NSp NS
Chen et al (1991) Recuts 80 8 DCIS 21 (28) 3.2 Distant 50.05 U ND
68 IDC
4 ILC 2 (50)
Noe ¨l et al (1991) Original slides 168 NSp 31 (18.5) 10 Local
Distant
Death
NS U Local
Distant
Death
NS
Byrne et al (1992) Original slides 39 35 IDC 5 (13) 3.6 NSp 50.001 U NSp 50.001
4 ILC
de Mascarel et al (1992) Original slides 218 129 IDC 13 (10) 15.6 DFP 50.01 U SS NS
0.01 M 0.02
89 ILC 37 (41) 9.3 DFP NS U SS NS
Hainsworth et al (1993) Recuts 343 NSp 41 (12) 6.5 DFI NS U OS NS
50.05 M 50.05
Elson et al (1993) Recuts 97 NSp 20 (20.6) 5.7 NSp NS U NSp NS
Nasser et al (1993) Serial recuts 159 140 IDC DFS NS U OS NS
4 colloid 22 (14) 10
3 medullary
12 ILC
McGuckin et al (1996) Serial recuts 208 163 IDC 41 (25) DFS S. U OS S
Combination of 29 ILC 11 (38) 7.6 50.005 M NS
HES+IHS 16 others 1 (6)
Cote et al (1999) Serial recuts 736 595 IDC 112 (19) DFS 0.01
a U OS 0.003
a
HES and IHS 51 ILC 20 (39) 12 M 0.007
90 others 16 (18)
de Mascarel Original slides 218 129 IDC 13 (10) 24 DFP NS U OS NS
(present study) 89 ILC 37 (41) 18 NS M NS
aIn the post-menopausal group of patients less than 65 years old. U=univariate analysis; M=multivariate analysis; NS=not signiﬁcant; NSp=not speciﬁed in the original study;
ND=not done in the study; DFP=disease-free probability; DFI=disease-free interval; SS=speciﬁc survival (deaths from breast cancer); OS=overall survival; MFP=metastasis-free
probability.
1
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Figure 3 Metastasis-free survival according to presence or absence of node metastases detected by immunohistochemistry (IHM) in ILC group.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(1), 70–74immunohistochemistry and cases that are detectable only with
immunohistochemical staining. The percentages of IHM according
to the histological tumour type have been studied in only four
reports (Trojani et al, 1987a,b; Byrne et al, 1992; McGuckin et
al, 1996; Cote et al, 1999). When speciﬁed, deﬁnitions of events
taken into account to calculate survival probabilities were heteroge-
neous and median follow-up was variable. All these differences in
methodologies explain why neither the detection rates of these
IHM nor their prognostic signiﬁcance are comparable. IHM were
associated with poorer prognosis in ﬁve studies (Sedmak et al,
1989; Byrne et al, 1992; Hainsworth et al, 1993; McGuckin et al,
1996; Cote et al, 1999). This prognostic signiﬁcance is debatable
due to the small number of patients (Sedmak et al, 1989; Byrne
et al, 1992), the short median follow-up (Hainsworth et al,
1993), and to the fact that IHM were detected not only by immu-
nohistochemistry but by a combination of morphological analysis
on haematoxylin-stained slides and immunohistochemistry
(McGuckin et al, 1996). In the study by Cote et al (1999), IHM
were associated with a shorter survival by univariate analysis in
the under 65-year-old post-menopausal group of patients corre-
sponding to 7% (53 out of 736) of the patients in their series.
Multivariate analysis was performed on groups of patients stratiﬁed
according to oestrogen receptor (ER) status (progesterone receptor
status not speciﬁed), so the prognostic signiﬁcance (value of risk)
of IHM vs ER status is debatable. Furthermore, the relative impor-
tance by multivariate analysis of IHM vs tumour size, grade and
vascular invasion was not speciﬁed. Lastly, perioperative
chemotherapy was not effective in the group of patients in whom
IHM were found.
CONCLUSION
On the whole, the pejorative signiﬁcance of breast axillary node
metastases detected by immmunohistochemistry is debatable. It
has to be proved before using immunohistochemical stainings as
a standard in the sentinel lymph node technique. In conclusion:
(1) our results emphasise the importance of length of follow-up
in assessing the signiﬁcance of metastases detected by immunohis-
tochemistry; (2) in the literature there is no ﬁrm evidence
underlining the prognostic signiﬁcance of such metastases, and
(3) more prospective and concordant studies are necessary to
conﬁrm or not the prognostic signiﬁcance of metastases detected
by immunohistochemistry. Therefore, a standard methodology is
required in the pathological assessment of axillary lymph nodes.
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